[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Daptomycin Market Report: Trends, Forecast and Competitive Analysis to 2030

January 2024 | 150 pages | ID: DA370737D768EN
Lucintel

US$ 4,850.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.

Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
1. EXECUTIVE SUMMARY


2. GLOBAL DAPTOMYCIN MARKET : MARKET DYNAMICS

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Daptomycin Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Daptomycin Market by Indication
  3.3.1: Complicated skin structure infections
  3.3.2: Bacteremia
3.4: Global Daptomycin Market by Age Group
  3.4.1: Pediatric
  3.4.2: Adult
3.5: Global Daptomycin Market by Strength
  3.5.1: 300mg
  3.5.2: 500mg

4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030

4.1: Global Daptomycin Market by Region
4.2: North American Daptomycin Market
  4.2.2: North American Daptomycin Market by Strength: 300mg and 500mg
4.3: European Daptomycin Market
  4.3.1: European Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
  4.3.2: European Daptomycin Market by Strength: 300mg and 500mg
4.4: APAC Daptomycin Market
  4.4.1: APAC Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
  4.4.2: APAC Daptomycin Market by Strength: 300mg and 500mg
4.5: ROW Daptomycin Market
  4.5.1: ROW Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
  4.5.2: ROW Daptomycin Market by Strength: 300mg and 500mg

5. COMPETITOR ANALYSIS

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis

6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS

6.1: Growth Opportunity Analysis
  6.1.1: Growth Opportunities for the Global Daptomycin Market by Indication
  6.1.2: Growth Opportunities for the Global Daptomycin Market by Age Group
  6.1.3: Growth Opportunities for the Global Daptomycin Market by Strength
  6.1.4: Growth Opportunities for the Global Daptomycin Market by Region
6.2: Emerging Trends in the Global Daptomycin Market
6.3: Strategic Analysis
  6.3.1: New Product Development
  6.3.2: Capacity Expansion of the Global Daptomycin Market
  6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Daptomycin Market
  6.3.4: Certification and Licensing

7. COMPANY PROFILES OF LEADING PLAYERS

7.1: Teva Pharmaceuticals Industries
7.2: Merck
7.3: Cipla
7.4: Pfizer
7.5: BE Pharmaceuticals
7.6: Reddy’s Laboratories
7.7: Mylan
7.8: Fresenius Kabi
7.9: Nichi-Iko Pharmaceutical
7.10: Novo Holdings


More Publications